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Objective: Long-term results of surgical vessel reconstruction are compromised by restenosis caused by neoin-
timal hyperplasia. Recent studies suggest that reduced cyclic guanosine monophosphate signaling is associated
with neointima formation. In a rat model of endarterectomy, we investigated the effect of pharmacologic inhibi-
tion of cyclic guanosine monophosphate degradation on neointima formation by using the selective phosphodi-
esterase-5 inhibitor vardenafil.
Methods: Carotid endarterectomy was performed in male Sprague–Dawley rats by means of incision of the right
common carotid artery with removal of intima. Four groups were studied: unoperated control rats (n ¼ 4), sham-
operated rats (n ¼ 9), control rats with endarterectomy (n ¼ 9), or endarterectomized rats treated with vardenafil
(10 mg/kg/day) postoperatively (n ¼ 9). After 3 weeks, vessel compartment areas were measured by means of
conventional microscopy with hematoxylin and eosin staining. Immunohistochemical analysis was performed
to confirm neointima formation and the local cyclic guanosine monophosphate content. Plasma levels of cyclic
guanosine monophosphate were determined by means of enzyme immunoassay. Student’s t test was used for sta-
tistical evaluation.
Results: Immunohistochemical analysis demonstrated intensive staining for transforming growth factor b1 and
a-smooth muscle actin in the control neointima. Vardenafil significantly reduced the stenosis grade (24.64% 
7.46% vs 54.12%  10.30% in the control group, P<.05) and expression of transforming growth factor b1, as
well as a-smooth muscle actin, in the neointima. The immunohistochemical score for cyclic guanosine mono-
phosphate was higher in the treated neointima (4.80  0.76 vs 2.84  0.40 in the control group, P< .05), and
increased plasma cyclic guanosine monophosphate levels were found by means of enzyme immunoassay as
well (84.65  12.77 pmol/mL vs 43.50  3.30 pmol/mL in the control group, P< .05).
Conclusions: Treatment with vardenafil can be considered a new possibility to prevent neointimal hyperplasia
after endarterectomy.Carotid endarterectomy is the standard treatment of severe
carotid stenosis.1 Operative repair is not without potential
complications, one of which is postoperative restenosis.
Despite technical problems, the main cause of early reste-
nosis after surgical vessel reconstruction is neointimal
hyperplasia. Risk factors for early restenosis include alter-
ations in the complement system,2 increased serum growth
factor levels,3 or changes in the hemostatic factors.4
Ischemia–reperfusion injury and endothelial damage
promote neointima formation. In contrast with early resteno-
sis, late restenosis is due to the progression of primary
atherosclerosis.5 Pathologically, the following processes
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cle cells (SMCs) from the medial to the intimal layer, the
proliferation of SMCs, the deposition of extracellular matrix
material, and alterations in apoptosis of neointimal cells.6
Our previous studies showed that nitro-oxidative stress plays
an important role in neointima formation after vascular
injury, which could be effectively decreased by the inhibi-
tion of the peroxynitrite–poly (adenosine diphosphate–
ribose) polymerase (PARP) pathway.7 In addition, evidence
is growing that reduced nitric oxide (NO)–cyclic guanosine
monophosphate (cGMP) signaling plays an important role in
the pathogenesis of neointima formation,8 which could be
prevented by local delivery of NO9 or by using a short-acting
NO donor in the perivascular area of the injured rat carotid
artery.10 Furthermore, neointimal proliferation could also
be attenuated by endothelial NO synthase gene transfer in
a rat model of balloon injury.11 Although there are several
works that studied the effects of NO–cGMP signaling in
the reduction of neointima formation through the adminis-
tration of NO donors, to the best of our knowledge, there
is little research on the effects of cGMP through its altered
breakdown. A benzyl indazole derivative used in 2 different
studies decreased neointimal hyperplasia; the drug has
partial phosphodiesterase-5 inhibitory effects.12,13 Otherrgery c June 2009
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TAbbreviations and Acronyms
cGMP ¼ cyclic guanosine monophosphate
NO ¼ nitric oxide
PARP ¼ peroxynitrite–poly (adenosine
diphosphate–ribose) polymerase
PKG ¼ protein kinase G
SMC ¼ smooth muscle cell
TGF ¼ transforming growth factor
TUNEL ¼ terminal deoxynucleotidyl transferase–
mediated dUTP-biotin nick end labeling
phosphodiesterases have been shown to have beneficial
effects on neointimal hyperplasia that are not selective for
cGMP metabolism.14 Vardenafil is a novel phosphodiester-
ase-5 inhibitor drug that acts through the inhibition of cGMP
degradation. This drug is already in clinical use for erectile
dysfunction and pulmonary hypertension, but it has not
been tested in cardiovascular diseases thus far or in the
treatment of stenosis formation after intra-arterial injury.
Because decreased cGMP signaling plays a central role in
neointima formation leading to luminal stenosis, we investi-
gated, in our rat model of carotid endarterectomy, whether
neointimal hyperplasia can be prevented by the treatment
with vardenafil. We also wanted to test the effect of vardena-
fil treatment on local and systematic cGMP levels. In addi-
tion, we analyzed whether phosphodiesterase-5 inhibition
affects neointimal proliferation and neointimal cell apopto-
sis after endarterectomy.
MATERIALS AND METHODS
Rat Carotid Endarterectomy Model
The protocol was approved by the Regional Ethical Committee for
Laboratory Animal Use and conformed with the ‘‘Guide for the care and
use of laboratory animals’’ published by the United States National Insti-
tutes of Health (publication no. 85-23, revised 1996). Eighteen male
Sprague–Dawley rats (250–300 g body weight) underwent right carotid
endarterectomy with removal of the intima, and 9 rats underwent a sham
operation. After adequate anesthesia with an intraperitoneal injection of ket-
amine hydrochloride (100 mg/kg) and xylazine hydrochloride (5 mg/kg),
the right common carotid artery was exposed by using a dissecting
microscope through a midline cervical incision. A longitudinal arteriotomy
was made with a corneal blade and extended to 6 mm with microscissors
after clamping of the right common carotid artery. A sterile cotton-tipped
applicator immersed in saponin (0.1%) was rubbed on the inner vessel
surface to denude the endothelium. This chemical skinning technique was
used to preserve vascular smooth muscle function postoperatively.15,16
The arteriotomy was closed with a running 9–0 Ethilon monofilament nylon
suture (Ethicon, Inc, Somerville, NJ). The superficial cervical muscles and
skin were closed with running 4–0 absorbable sutures. Animals were started
postoperatively on a standard rat diet and provided with water ad libitum.
Experimental Groups
Animals were divided into 4 groups: (1) unoperated control rats (n ¼ 4)
for measurement of intact plasma; (2) sham-operated animals (n ¼ 9) in
which the carotid artery was not incised; (3) a control carotid endarterec-The Journal of Thoracic and Ctomy group (n ¼ 9) treated with the vehicle orally; and (4) the treatment
group (n ¼ 9), which received the phosphodiesterase-5 inhibitor vardenafil
(10 mg/kg daily, administered orally) dissolved in distilled water. This dose
was drawn from recent literature reports showing efficacy of vardenafil in rat
models.17
Perfusion Fixation Protocol
After 21 days, the carotid arteries were perfusion fixed and harvested.
First, the inferior vena cava was transected and the abdominal aorta was
cannulated. Normal saline solution was infused at 100 mm Hg until the
vena cava effluent ran clear, and then a solution of 4% formaldehyde
was infused at a constant pressure of 100 mm Hg in an equal volume
to the saline infusion (200 mL) to complete the perfusion-fixation
process.
Histologic Analysis
Morphometric analysis was performed in 3 hematoxylin and eosin–
stained cross-sections of each animal (proximal, mid, and distal regions
of the operated vessel segment) by using computer-aided planimetry
(Q-Win; Leica, Wetzlar, Germany). Luminal, intimal, and medial dimen-
sions were computed by using the internal and external elastic laminae as
delimeters. The percentage of stenosis was calculated by using the ratio
between the neointimal area and the original luminal area. In addition, the
neointimal/medial area ratio was calculated. From the 3 cross-sections,
the mean was calculated for each animal, and then again the mean was
calculated for the different experimental groups (n ¼ 9 animals per group),
and these were compared between groups.
Immunohistochemical Staining
Immunohistochemical analysis was done in 3 representative cross-sec-
tions of each animal by using the avidin–biotin method. Local cGMP
content was determined to test the phosphodiesterase-5 activity. The
primary antibody used for this staining was rabbit polyclonal anti-cGMP
antibody (AbD Serotec, Dusseldorf, Germany). We used transforming
growth factor b1 (TGF-b1) staining to confirm proliferation activity. The
TGF-b system has been identified as a key defect of inhibitory systems,
which regulates atherosclerosis and other injury-induced hyperplasias,
such as restenosis. The primary antibody for TGF-b1 was rabbit polyclonal
immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, Calif).
a-Smooth muscle actin staining has been used to prove that neointimal cells
originate from the medial layer of the injured artery. The primary antibody
for a-smooth muscle actin was mouse monoclonal immunoglobulin
(a-Smooth Muscle Actin Immunohistology Kit; Sigma, Steinheim,
Germany). The concentration that was optimal for staining was evaluated
by testing different dilution series in a pilot study. The following dilutions
of antibodies were used: 1:40 for TGF-b1 and 1:1000 for cGMP. a-Smooth
muscle actin undiluted antibody solution was supplied in the immunohistol-
ogy kit.18 Negative controls were performed by omitting the primary anti-
body. Immunohistochemical staining was evaluated by using the COLIM
software package (Pictron Ltd, Budapest, Hungary). A digital camera was
used to input microscopic pictures from a low-power (163–403) magnifi-
cation of the whole section and a high-power (4003) examination of 5
adjacent fields. First, positively stained areas were separated from each other
and from the background based on the intensity of different colors in the
specimen. The colors were measured by using densitometric analysis and
put in 4 color classes: 1 class for background staining and 3 classes for
positively stained areas. On the basis of the measured intensity, the color
classes were coupled with score values as follows: 0, no positive staining;
1, weak staining; 2, intermediate staining; and 3, extensive staining. The
program automatically measured the area of the objects in each class in
each field, assigned an area score (1, 10% positive cells; 2, 11% to
50% positive cells; 3, 51% to 80% positive cells; 4,>80% positive cells),
and calculated an average score for the whole picture (intensity scoreardiovascular Surgery c Volume 137, Number 6 1509
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with the average of the 5 adjacent fields.
Terminal Deoxynucleotidyl Transferase–Mediated
dUTP-Biotin Nick End Labeling Assay
Terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick end
labeling (TUNEL) is a common method for detecting DNA fragmentation
that results from apoptosis or oxidative DNA damage. The cells with clear
nuclear labeling were defined as TUNEL positive. These TUNEL-positive
cells were counted in 1000 mm2 of neointimal tissue segments and were
compared between the control endarterectomized and treatment groups.
The number of tissue sections in each group was the same as for the morpho-
metric analysis.6
Enzyme Immunoassay
Blood samples were collected from each animal in the unoperated,
control endarterectomized, and treatment groups. Plasma was separated
and placed immediately in liquid nitrogen. cGMP concentrations were
determined by using competitive enzyme immunoassay with a cGMP
enzyme immunoassay kit (Amersham, Piscatway, NJ).
Statistical Analysis
Values are expressed as means  SEM. Statistical analysis was
performed with the Origin 7 statistical software product (OriginLab,
Northampton, Mass). Two group comparisons were determined by using
the Student’s t test.RESULTS
Effects of the Phosphodiesterase-5 Inhibition on
Neointima Formation and on the Expression of
TGF-b1 and a-Smooth Muscle Actin
Three weeks after in vivo endothelial denudation, concen-
tric neointima was found in the control endarterectomized
group, resulting in a 54.12% stenosis of the original luminal
area (Figure 1). In the phosphodiesterase-5 inhibitor–treated
group, significant reduction of neointima formation was
observed. Stenosis was 24.64% in this group (P<.05, treat-
ment group compared with control endarterectomy group).
In addition, the neointimal/medial area ratio was calculated,
which was found to be significantly reduced after phospho-
diesterase-5 inhibition (0.50 vs 1.03 in the phosphodiester-
ase-5 inhibitor–treated group vs the control endarterectomy
group, P<.05). In the sham and unoperated groups, normal
morphologic structure was found with a single endothelial
cell layer.
Neointimal cells originate from the medial layer of the
injured de-endothelialized vessel by means of migration
and proliferation of vascular SMCs. To confirm this, we
detected a-smooth muscle actin in the neointimas of the
control and treated animals. Parallel to the extent of intimalFIGURE 1. Morphometric results and representative histologic cross-sections from the different groups (hematoxylin and eosin staining). A, Percentage of
stenosis (neointimal/original luminal area ratio). B, Neointimal/medial area ratio. C, Sham group. D, Control endarterectomy group with massive neointima
proliferation. E, Significantly less neointima formation after treatment with vardenafil. *P< .05 vs sham operation; yP< .05 vs control endarterectomy.
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immunoreactive a-smooth muscle actin was found in the
injured and treated vessels, whereas its levels were higher
in the control group (5.98  0.51 vs 8.27  0.73 in the
control group, P< .05, Figure 2). In addition, we used
TGF-b1 immunostaining. Usually, marked TGF-b1 staining
can be seen in proliferating tissues; therefore it is a useful
marker of the proliferation activity in the neointima. An
extensive TGF-b1 deposition was found in the control
group, and the immunohistochemical score for TGF-b1
was significantly less in the vardenafil-treated group (2.0
 0.3 vs 5.82  1.09 in the control group, P< .05).
Effects of the Phosphodiesterase-5 Inhibition on
Neointimal and Plasma cGMP Levels
To confirm that the effect of vardenafil on neointima for-
mation was related to the increase in cGMP levels seen inour endarterectomy model, we determined neointimal
cGMP content by means of immunohistochemistry, as
well as by measuring circulating cGMP levels by means of
enzyme immunoassay in deep-frozen plasma samples. As
shown in Figure 2, immunoreactivity for cGMP was signi-
ficantly higher in the neointimas of the vardenafil-treated
group compared with those of the control endarterectomized
group. Semiquantitative evaluation of all sections of both
groups indicated a significantly higher score for the phos-
phodiesterase-5 inhibitor–treated group compared with the
control group (4.80  0.76 vs 2.84  0.40 in the control
group, P<.05). The increased cGMP levels in the treatment
group could be shown systematically as well. Plasma cGMP
concentrations were almost twice as increased as in the con-
trol groups (84.65  12.77 pmol/mL vs 43.50  3.30 pmol/
mL and 38.20  2.18 in the control endarterectomy and
unoperated control groups, respectively; P< .05; Figure 3).E
TFIGURE 2. Representative photomicrographs (B–C, E–F, and H–I) and semiquantitative scoring (A, D, and G) of immunohistochemical staining for trans-
forming growth factor b1 (TGF-b1; red stain, A–C) and a-smooth muscle actin (Alpha-sm actin; brown stain, D–F) and for cyclic guanosine monophosphate
(cGMP; red stain) in the neointima (G–I) are shown in the control endarterectomy group (B, E, and H) and the vardenafil treatment group (C, F, and I).
m, media; ni, neointima. *P< .05 vs control endarterectomy.
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plasma cGMP concentrations between the 2 control groups
(43.50  3.30 in the control endarterectomy group vs
38.20  2.18 in the unoperated control group).
Effects of the Phosphodiesterase-5 Inhibition on
Apoptosis of Neointimal Cells
To test a possible contribution of apoptosis to the decrease
of neointimal hyperplasia after treatment with vardenafil, we
performed the TUNEL assay on each section from both
groups. As shown in Figure 4, we did not find a significant
difference in the apoptotic cell counts in the same unit (1000
mm2) of the control and treated neointimas (4.23  0.43 vs
4.44  0.64 in the control group).
DISCUSSION
Recent studies show that reduced cGMP signaling is asso-
ciated with neointimal proliferation, which is the main cause
of restenosis after endarterectomy.8 It has also been shown
that an NO donor can prevent neointimal hyperplasia in
a rat carotid artery injury model, as well as in a porcine cor-
onary injury model.9,10 Additionally, neointima formation
could be reduced by adenovirus-mediated transfer of the
endothelial NO synthase gene in a rat model of balloon
injury.11 To the best of our knowledge, it has not been tested
whether the selective inhibition of phosphodiesterase-5, the
enzyme which is responsible for cGMP degradation, would
also be capable of preventing neointima formation after end-
arterectomy. Some non–cGMP-specific phosphodiesterases
have been tested and showed beneficial effects on neointi-
mal hyperplasia.14 The benzyl indazole derivative YC-1
also decreased neointimal hyperplasia; nevertheless, this
FIGURE 3. Cyclic guanosine monophosphate (cGMP) plasma concentra-
tions (in picomoles per milliliter) measured by means of competitive en-
zyme immunoassay in the different groups. *P < .05 vs unoperated
control and control endarterectomy.1512 The Journal of Thoracic and Cardiovascular Sdrug has only a partial phosphodiesterase-5 inhibitory
effect.12,13 The primary aim of our present study was to
test the effectiveness of the novel selective phosphodiester-
ase-5 inhibitor vardenafil in a rat model of carotid endarter-
ectomy. We previously showed, in the same rat carotid
endarterectomy model, that 21 days after endothelial denu-
dation, significant neointimal hyperplasia and ongoing neo-
intima development is detectable; therefore we used the
same timeframe in this study as well.15 The main results
of the present study are that neointima formation and expres-
sion of different neointimal markers were attenuated by
treatment with the phosphodiesterase-5 inhibitor vardenafil.
Treatment with vardenafil significantly increased plasma
cGMP levels, as well as neointimal cGMP content, as deter-
mined at the end of the 3-week follow-up period. Compara-
ble neointimal reduction could be achieved in our previous
studies by using the PARP inhibitor or the combination of
brachytherapy and the PARP inhibitor.7,19
Endothelially derived NO is able to activate the soluble
guanylate cyclase in vascular SMCs, which is responsible
for cGMP synthesis. cGMP mediates its intracellular effects
through activation of specific cGMP-dependent protein
kinases (protein kinase G [PKG]). The main effects of
cGMP, which could be involved in decreased neointima
formation, are as follows: inhibition of migration and prolif-
eration of vascular SMCs and alterations of oxidative and
apoptotic signaling.20,21
A possible downstream signaling mechanism that contrib-
utes to the beneficial effects of phosphodiesterase-5 inhibi-
tion on neointima formation acts through PKG, as was
shown by Sinnaeve and colleagues22 in a PKG-overex-
pressed rat model. In another study by the same authors,
the antiproliferative and antimigratory effects of soluble
guanylate cyclase gene transfer after balloon injury in rats
were demonstrated, which again confirms the role of
FIGURE 4. Terminal deoxynucleotidyl transferase–mediated dUTP-bio-
tin nick end labeling (TUNEL)–positive cell count in 1000 mm2 of neointima
in the control endarterectomy and vardenafil groups.urgery c June 2009
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In connection with these results, Tulis and associates13
showed reduced postangioplasty stenosis after enhanced
cGMP signaling by using a benzyl indazole derivate (YC-1)
that can stimulate soluble guanylate cyclase (sGC) in vascu-
lar endothelium and SMCs. The benzyl indazole derivate
used in this study has, in addition, a phosphodiesterase-5–
inhibiting secondary effect as well. Liu and coworkers12
showed similar results on neointimal hyperplasia using
YC-1. Several mechanisms for the potent protective actions
of vardenafil on neointima formation can be suggested based
on results from in vitro studies. Yu and colleagues21 showed
an inhibition of DNA synthesis associated with diminution
in mitogen-activated protein kinase levels after enhanced
cGMP signaling. Other work showed cGMP-induced inhibi-
tion in anti-mitogen cyclin-dependent kinase activity and
cyclin D1 expression, leading to the suppression of cell cycle
in vascular cells.24
An interesting new finding of our study is a significant
reduction of TGF-b1 immunoreactivity in the neointima
after treatment with the phosphodiesterase-5 inhibitor
vardenafil. It has been shown in several studies that the
TGF-b system contributes to neointimal proliferation and
that neointimal hyperplasia could be suppressed by using
TGF-b antibody.25,26 TGF-b1 is overexpressed in fibropro-
liferative vascular lesions, allowing a slow but uncontrolled
growth while overproducing extracellular matrix compo-
nents. In addition, Saura and coworkers27 showed that
endothelial cells treated with an NO donor exhibited a
decreased response to TGF-b, resulting in a downregulation
of TGF-b target genes.28 Taking these findings together
with our present results, the following explanation can be
given for the linkage between cGMP and TGF-b1 signal-
ing during neointima formation: NO decreases TGF-b1
signaling through increases in cGMP levels, which finally
leads to reduced vascular SMC proliferation. In our opinion
the same linkage is present in the phosphodiesterase-5
inhibitor–treated neointima because treatment with varde-
nafil leads to an increased cGMP signaling similar to the
effect of NO. The observed reduction in TGF-b1 levels
after treatment with vardenafil in our study might be
a primary consequence of phosphodiesterase-5 inhibition
because of interrupted cytokine production rather than
a secondary phenomenon. Nevertheless, we have no direct
evidence in the present study or in the literature that would
support this hypothesis. In addition to the decreased
TGF-b1 immunoreactivity after treatment with vardenafil,
we found decreased expression in a-smooth muscle actin
as well. Cell culture studies suggest that vascular SMC mi-
gration is attenuated by the NO–cGMP–PKG pathway.20,29
On the other hand, cGMP-increasing agents have been
found to prevent actin polymerization and thereby decrease
vascular cell migration. We can speculate that decreased
a-smooth muscle actin expression found in the treated neo-The Journal of Thoracic and Caintima in our study might be due to decreased proliferation
and migration.
Chiche and associates30 showed proapoptotic effects of
the NO–cGMP pathway in cultured rat pulmonary artery
SMCs after adenovirus-mediated gene transfer of cGMP-
dependent protein kinase. To test a possible contribution
of apoptosis to the reduction of neointimal hyperplasia after
treatment with phosphodiesterase-5 inhibitor, we performed
the TUNEL assay. No effects were found in our in vivo
model of restenosis, which leads us to the conclusion that
attenuated neointima formation might be due to the
decreased proliferation activity rather than to enhanced neo-
intimal apoptosis. Nevertheless, we cannot exclude other
mechanisms to be involved in the beneficial effects of phos-
phodiesterase-5 inhibition on neointimal hyperplasia. Vaso-
dilatation or phosphorylation of protein kinases could also
influence this process. Unfortunately, we do not have any
direct evidence regarding this issue in our present study;
further studies are necessary to investigate these issues.
Limitations of the Study
The carotid endarterectomy model used in this study does
not resemble the complex situation of a severely diseased
atherosclerotic artery in a patient. However, the native rat ca-
rotid artery is an established model of intimal hyperplasia.15
In addition, it has to be noted that animal models of athero-
sclerosis also lack direct comparability with the human situ-
ation. Even knockout models have pathophysiologic and
phenotypic differences regarding plaque cause and morphol-
ogy. However, further studies with animal models of athero-
sclerosis are warranted in the future to address this issue.
CONCLUSION
Treatment with the selective phosphodiesterase-5 inhibitor
vardenafil significantly suppressed neointimal hyperplasia af-
ter surgical endarterectomy in a rat model. These results sug-
gest a potential therapeutic role of vardenafil in preventing
neointima formation and restenosis after endarterectomy.
The expert technical assistance of H. Ziebart and G. Piecha is
gratefully acknowledged.
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